شرح

An orphan drug is a medicine for the diagnosis, prevention or treatment of a life-threatening or chronically debilitating condition that is rare or where the medicine is unlikely to generate sufficient profit to justify research and development costs. They are orphans because the pharmaceutical industry has little interest under normal market conditions in developing and marketing drugs intended for only a small number of patients suffering from very rare conditions. The global orphan drugs market is set to grow by US$ 69 میلیارد در طول 2021-2027, رشد با نرخ رشد مرکب سالانه (CAGR) از 5.5% در طول دوره پیش بینی, بر اساس داده ها و شرکت تحلیلی StrategyHelix. Availability of exclusivity for orphan drugs, rising prevalence of rare diseases, favorable government policies are expected to boost the market growth in the coming years.

این گزارش داده های به روز اندازه بازار را برای دوره ارائه می دهد 2017-2020 و پیش بینی به 2027 covering key market aspects like sales value for orphan drugs. The global orphan drugs market is segmented on the basis of drug type, top selling drug, disease type, و منطقه. By drug type, it is categorized into biological drugs, and non-biological drugs. The biological drugs segment held the largest market share in 2020. By top selling drug, the orphan drugs market is divided into Revlimid, Tafinlar, Hemlibra, Darzalex, Kyprolis, Myozyme, Vyndaqel, Soliris, Ninlaro, Imbruvica, و دیگران. The Revlimid segment accounted for the largest market share in 2020. Based on disease type, the orphan drugs market is divided into oncology, blood disorders, central nervous system, respiratory system, immunomodulators, cardiovascular therapies, و دیگران.

The report has profiled some of the key players of the market such as AbbVie Inc., Alexion Pharmaceuticals Inc., Amgen Inc., AstraZeneca plc, Biogen Inc., BioMarin Pharmaceutical Inc., Bristol-Myers Squibb Company, Celgene Corporation, CSL Behring GmbH, Eisai Co. Ltd., اف. Hoffmann-La Roche AG, Incyte Corporation, Jiangsu Hengrui Medicine Co. Ltd., جانسون & جانسون, Novartis AG, Pfizer Inc., Sanofi S.A., Syros Pharmaceuticals Inc., Takeda Pharmaceutical Co. Ltd., Vertex Pharmaceuticals Inc..

این گزارش منبع ارزشمندی برای شرکت ها و سازمان های فعال در این صنعت است. It provides a cohesive picture of the orphan drugs market to help drive informed decision making for industry executives, سیاست گذاران, علمی, و تحلیلگران.

دامنه گزارش

Drug type: biological drugs, and non-biological drugs
Top selling drug: Revlimid, Tafinlar, Hemlibra, Darzalex, Kyprolis, Myozyme, Vyndaqel, Soliris, Ninlaro, Imbruvica, و دیگران
Disease type: oncology, blood disorders, central nervous system, respiratory system, immunomodulators, cardiovascular therapies, و دیگران
منطقه: آمریکای شمالی, آسیا و اقیانوسیه, اروپا, و بقیه جهان (ROW)
سال های در نظر گرفته شده: این گزارش دوره را پوشش می دهد 2017 به 2027

مزایای کلیدی برای ذینفعان

Get a comprehensive picture of the global orphan drugs market
شناسایی استراتژی های منطقه ای و اولویت های استراتژیک بر اساس داده ها و تحلیل های محلی
بخش های رشد و روند سرمایه گذاری را مشخص کنید
Understand what the future of the global orphan drugs market looks like
چشم انداز رقابتی و پنجره فرصت را شناسایی کنید

فهرست مطالب

1. تعریف بازار
2. روش تحقیق
3. داده های بازار & چشم انداز
3.1 ارزش بازار
3.2 پیش بینی ارزش بازار
4. Orphan Drugs Market by Drug Type
4.1 Biological Drugs
4.2 Non-Biological Drugs
5. Orphan Drugs Market by Top Selling Drug
5.1 Revlimid
5.2 Tafinlar
5.3 Hemlibra
5.4 Darzalex
5.5 Kyprolis
5.6 Myozyme
5.7 Vyndaqel
5.8 Soliris
5.9 Ninlaro
5.10 Imbruvica
5.11 دیگران
6. Orphan Drugs Market by Disease Type
6.1 Oncology
6.2 Blood Disorders
6.3 Central Nervous System
6.4 Respiratory System
6.5 Immunomodulators
6.6 Cardiovascular Therapies
6.7 دیگران
7. Orphan Drugs Market by Region
7.1 آمریکای شمالی
7.2 آسیا و اقیانوسیه
7.3 اروپا
7.4 بقیه دنیا (ردیف)
8. مشخصات شرکت
8.1 AbbVie Inc.
8.2 Alexion Pharmaceuticals Inc.
8.3 Amgen Inc.
8.4 AstraZeneca plc
8.5 Biogen Inc.
8.6 BioMarin Pharmaceutical Inc.
8.7 Bristol-Myers Squibb Company
8.8 Celgene Corporation
8.9 CSL Behring GmbH
8.10 Eisai Co., Ltd.
8.11 اف. Hoffmann-La Roche AG
8.12 Incyte Corporation
8.13 Jiangsu Hengrui Medicine Co., Ltd.
8.14 جانسون & جانسون
8.15 Novartis AG
8.16 Pfizer Inc.
8.17 Sanofi S.A.
8.18 Syros Pharmaceuticals, شرکت.
8.19 Takeda Pharmaceutical Co. Ltd.
8.20 Vertex Pharmaceuticals, شرکت.
9. ضمیمه
9.1 درباره StrategyHelix
9.2 سلب مسئولیت